Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent

R. E. Coleman, Timothy R DeGrado, S. Wang, S. W. Baldwin, M. D. Orr, R. E. Reiman, D. T. Price

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The purpose of this study was to develop and evaluate an F-18 labeled choline tumor imaging agent. FCH was synthesized through the intermediate F-18 fluorobromomethane that was used to alkylate dimethylethanolamine. The isolated FCH was evaluated in PC-3 human prostate cancer cells, PC-3 human prostate cancer xenograft studies, and human prostate and brain tumor patients. FCH was accumulated at a slightly lower rate than FDG in the cultures of PC-3 cells. Inhibition of choline transport and phosphorylation by hemicholinium-3 resulted in a 90% decrease in FCH uptake without altering FDG uptake. FCH had a similar biodistribution as C-14 choline in mice, with the liver and kidneys being the primary sites of uptake. Tumor uptake of FCH and FDG were comparable at 45-60 mins after injections. The tumor:blood ratio was higher for FCH (5.3 ± 2.4) than for FDG (3.2 ± 0.3). Brain uptake of FCH was 10% that of FDG. FCH-PET studies were compared to FDG-PET studies. In the prostate cancer patients, more lesions have been seen on the FCH studies than on the FDG studies, and the standardized uptake values (SUV) have been higher with the FCH. Decreases in FCH-PET SUV have been noted in patients treated by androgen deprivation. Patients with suspected recurrent brain tumors have had more clearly defined abnormal accumulation on the FCH-PET scans than on the FDG-PET scans. The FCH is not accumulated by normal cortex. FCH is a promising imaging agent for the evaluation of metastatic prostate cancer and recurrent brain tumor.

Original languageEnglish (US)
Pages (from-to)147
Number of pages1
JournalClinical Positron Imaging (Netherlands)
Volume3
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Neoplasms
Brain Neoplasms
Prostatic Neoplasms
Choline
fluorocholine
Positron-Emission Tomography
Deanol
Hemicholinium 3
Heterografts
Androgens
Prostate
Phosphorylation
Kidney
Injections
Liver
Brain

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. / Coleman, R. E.; DeGrado, Timothy R; Wang, S.; Baldwin, S. W.; Orr, M. D.; Reiman, R. E.; Price, D. T.

In: Clinical Positron Imaging (Netherlands), Vol. 3, No. 4, 2000, p. 147.

Research output: Contribution to journalArticle

Coleman, R. E. ; DeGrado, Timothy R ; Wang, S. ; Baldwin, S. W. ; Orr, M. D. ; Reiman, R. E. ; Price, D. T. / Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. In: Clinical Positron Imaging (Netherlands). 2000 ; Vol. 3, No. 4. pp. 147.
@article{6698b667f20245f7afadbf7ccdb9bb06,
title = "Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent",
abstract = "The purpose of this study was to develop and evaluate an F-18 labeled choline tumor imaging agent. FCH was synthesized through the intermediate F-18 fluorobromomethane that was used to alkylate dimethylethanolamine. The isolated FCH was evaluated in PC-3 human prostate cancer cells, PC-3 human prostate cancer xenograft studies, and human prostate and brain tumor patients. FCH was accumulated at a slightly lower rate than FDG in the cultures of PC-3 cells. Inhibition of choline transport and phosphorylation by hemicholinium-3 resulted in a 90{\%} decrease in FCH uptake without altering FDG uptake. FCH had a similar biodistribution as C-14 choline in mice, with the liver and kidneys being the primary sites of uptake. Tumor uptake of FCH and FDG were comparable at 45-60 mins after injections. The tumor:blood ratio was higher for FCH (5.3 ± 2.4) than for FDG (3.2 ± 0.3). Brain uptake of FCH was 10{\%} that of FDG. FCH-PET studies were compared to FDG-PET studies. In the prostate cancer patients, more lesions have been seen on the FCH studies than on the FDG studies, and the standardized uptake values (SUV) have been higher with the FCH. Decreases in FCH-PET SUV have been noted in patients treated by androgen deprivation. Patients with suspected recurrent brain tumors have had more clearly defined abnormal accumulation on the FCH-PET scans than on the FDG-PET scans. The FCH is not accumulated by normal cortex. FCH is a promising imaging agent for the evaluation of metastatic prostate cancer and recurrent brain tumor.",
author = "Coleman, {R. E.} and DeGrado, {Timothy R} and S. Wang and Baldwin, {S. W.} and Orr, {M. D.} and Reiman, {R. E.} and Price, {D. T.}",
year = "2000",
doi = "10.1016/S1095-0397(00)00059-5",
language = "English (US)",
volume = "3",
pages = "147",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent

AU - Coleman, R. E.

AU - DeGrado, Timothy R

AU - Wang, S.

AU - Baldwin, S. W.

AU - Orr, M. D.

AU - Reiman, R. E.

AU - Price, D. T.

PY - 2000

Y1 - 2000

N2 - The purpose of this study was to develop and evaluate an F-18 labeled choline tumor imaging agent. FCH was synthesized through the intermediate F-18 fluorobromomethane that was used to alkylate dimethylethanolamine. The isolated FCH was evaluated in PC-3 human prostate cancer cells, PC-3 human prostate cancer xenograft studies, and human prostate and brain tumor patients. FCH was accumulated at a slightly lower rate than FDG in the cultures of PC-3 cells. Inhibition of choline transport and phosphorylation by hemicholinium-3 resulted in a 90% decrease in FCH uptake without altering FDG uptake. FCH had a similar biodistribution as C-14 choline in mice, with the liver and kidneys being the primary sites of uptake. Tumor uptake of FCH and FDG were comparable at 45-60 mins after injections. The tumor:blood ratio was higher for FCH (5.3 ± 2.4) than for FDG (3.2 ± 0.3). Brain uptake of FCH was 10% that of FDG. FCH-PET studies were compared to FDG-PET studies. In the prostate cancer patients, more lesions have been seen on the FCH studies than on the FDG studies, and the standardized uptake values (SUV) have been higher with the FCH. Decreases in FCH-PET SUV have been noted in patients treated by androgen deprivation. Patients with suspected recurrent brain tumors have had more clearly defined abnormal accumulation on the FCH-PET scans than on the FDG-PET scans. The FCH is not accumulated by normal cortex. FCH is a promising imaging agent for the evaluation of metastatic prostate cancer and recurrent brain tumor.

AB - The purpose of this study was to develop and evaluate an F-18 labeled choline tumor imaging agent. FCH was synthesized through the intermediate F-18 fluorobromomethane that was used to alkylate dimethylethanolamine. The isolated FCH was evaluated in PC-3 human prostate cancer cells, PC-3 human prostate cancer xenograft studies, and human prostate and brain tumor patients. FCH was accumulated at a slightly lower rate than FDG in the cultures of PC-3 cells. Inhibition of choline transport and phosphorylation by hemicholinium-3 resulted in a 90% decrease in FCH uptake without altering FDG uptake. FCH had a similar biodistribution as C-14 choline in mice, with the liver and kidneys being the primary sites of uptake. Tumor uptake of FCH and FDG were comparable at 45-60 mins after injections. The tumor:blood ratio was higher for FCH (5.3 ± 2.4) than for FDG (3.2 ± 0.3). Brain uptake of FCH was 10% that of FDG. FCH-PET studies were compared to FDG-PET studies. In the prostate cancer patients, more lesions have been seen on the FCH studies than on the FDG studies, and the standardized uptake values (SUV) have been higher with the FCH. Decreases in FCH-PET SUV have been noted in patients treated by androgen deprivation. Patients with suspected recurrent brain tumors have had more clearly defined abnormal accumulation on the FCH-PET scans than on the FDG-PET scans. The FCH is not accumulated by normal cortex. FCH is a promising imaging agent for the evaluation of metastatic prostate cancer and recurrent brain tumor.

UR - http://www.scopus.com/inward/record.url?scp=0001070596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001070596&partnerID=8YFLogxK

U2 - 10.1016/S1095-0397(00)00059-5

DO - 10.1016/S1095-0397(00)00059-5

M3 - Article

AN - SCOPUS:0001070596

VL - 3

SP - 147

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 4

ER -